The Role of Procalcitonin as a Prognostic Variable in Ovarian Cancer Patients at Dr. Soetomo General Hospital Surabaya

Irma Savitri Rasjad, Brahmana Askandar Tjokroprawiro

Abstract


Background: Procalcitonin (PCT) is a pro-hormone calcitonin that is strongly associated with bacterial infections, especially bacteremia. High serum PCT levels have been correlated with Lung cancer, colorectal cancer, thyroid cancer, and tumors of neuroendocrine. Studies on the role of PCT in ovarian tumors are still limited. This study aims to evaluate the role of PCT as a prognostic variable to determine the effectiveness of diagnostics in predicting ovarian cancer progression and metastasis.

Methods: This was a descriptive analytic study with a cross sectional design, conducted in Dr. Soetomo General Hospital Surabaya from July until October 2019. The subject selection used total quota sampling with inclusion criteria of female aged >12 or already menstruating, undergoing surgical removal of ovarian tumors either cystic or solid, with risk malignancy index (RMI) of >200, and with imaging results of suggestive ovarian malignancy. The data were analyzed descriptively using Chi-square test (α <0.05) and receiver operating characteristic (ROC) curve analysis.

Results: There were 36 study subjects; 38.9% of them are 40-49 years old; 77.8% have malignant tumors; and 22.2% of them have benign tumors with epithelial histopathology of 78.5% and nonepithelial of 21.4%. The optimal cut-off for PCT levels in ovarian tumors is 0.07 ng/ml with a 57.1% sensitivity and 87.5% specificity. There was a significant correlation between levels of PCT and ovarian tumors based on tumor types, postoperative tumor residues, and stages (p <0.05). There was no significant correlation between PCT levels and histopathological types and tumor grade.

Conclusions: Procalcitonin can be used as a prognostic variable to determine disease progression in ovarian tumors, especially in ovarian cancer.


Keywords


ovarian tumor, procalcitonin level, stage, resectability

References


Ezzati M, Abdullah A, Shariftabrizi A, et al. Recent advancements in prognostic factors of epithelial ovarian carcinoma. Int Sch Res Notices. 2014;2014:953509.

Chang L, Huang C, Lai M, et al. Prognostic factors in epithelial ovarian cancer: A population-based study. PLoS One. 2018;13(3):e0194993.

Chaftari AM, Hachem R, Reitzel R, et al. Role of procalcitonin and interleukin-6 in predicting cancer, and its progression independent of infection. PLoS One. 2015;10(7):e0130999.

Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005;2(1):3.

Keramidaris D, Koronakis N, Lagoudianakis EE, et al. Procalcitonin in patients with colorectal cancer. J BUON. 2013;18(3):623-8

Matzaraki V, Alexandraki KI, Venetsanou K, et al. Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis. Clin Biochem. 2007;40(5-6):336-42.

Hefler LA, Concin N, Hofstetter G, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res. 2008;14(3):710-4.

Liu Y, Chen S, Zheng C, et al. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer. BMC Cancer. 2017;17(1):285.


Full Text: PDF

DOI: 10.33371/ijoc.v15i3.718

Article Metrics

Abstract view : 101 times
PDF - 51 times

Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Indonesian Journal of Cancer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.